Business
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced a strat
About this update from Imunon, Inc.
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the company Phase 3 Study enrollment remains ahead of schedule and advances the company toward future BLA filing LAWRENCEVILLE, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced a strategic reorganization that will eliminate headcount not essential to the Phase 3 trial and redefine the job descriptions for additional employees to reduce operating expenses while supporting the company’s focused strategy to rapidly advance the pivotal OVATION 3 Phase 3 clinical trial in women with newly diagnosed advanced ovarian cancer. The company also announced that Khursheed Anwer, Ph.D., MBA, Executive Vice President and Chief Scientific Officer, who has been at IMUNON for nearly 12 years and who led the initial development of the company’s proprietary TheraPlas® platform technology, will retire effective February 20, 2026. “We have made significant progress and built strong momentum in 2025 with our lead IMNN-001 program, including reporting unprecedented Phase 2 clinical data at the 2025 ASCO Annual Meeting and in the peer-reviewed journal Gynecologic Oncology that showed a median 13-month increase in overall survival in combination with standard of care chemotherapy,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “Our highest priority now is to continue enrollment ahead of projections and to activate a full complement of clinical sites to complete this landmark research as quickly as possible. To support this, as we have always done, we have taken steps to improve our efficient use of resources. The flexibility of our workforce, a hallmark of Imunon’s ability to achieve its objectives, will ensure that we have the resources in place to build new levels of momentum in our Phase 3 trial in the months ahead.” “Dr. Khursheed Anwer’s decision to retire comes at a time of transition for the Company as we move to focus on the commercial potential of his career research, DNA-mediated immunotherapy. His scientific leadership, many contributions to advancing our business strategy, and lifelong commitment to patients have played a centra...